X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Applications - 27/Aug 05:08

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced...

Articles similaires

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Relief Therapeutics presents PKU GOLIKE study results at SSIEM 2024

pharmabiz.com - 03/Sep 00:00

Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...

Sorry! Image not available at this time

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

haei.org - 03/Sep 17:29

KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...

Sorry! Image not available at this time

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

drugs.com - 14/Sep 05:09

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...

Sorry! Image not available at this time

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Sorry! Image not available at this time

First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

drugs.com - 05/Sep 04:09

NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Sorry! Image not available at this time

New research network focuses on high-priority viruses

news.medical.net - 14/Sep 09:43

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most...

Sorry! Image not available at this time

New research network focuses on high-priority viruses

news.medical.net - 14/Sep 09:43

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most...

Les derniers communiqués